{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Guo X"],"funding":["NCATS NIH HHS","NIDDK NIH HHS","NCI NIH HHS","National Institutes of Health"],"pagination":["342-356"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8819981"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(2)"],"pubmed_abstract":["Background
Repeated administration of cisplatin causes CKD. In previous studies, we reported that the kidney-secreted survival protein renalase (RNLS) and an agonist peptide protected mice from cisplatin-induced AKI.Methods
To investigate whether kidney-targeted delivery of RNLS might prevent cisplatin-induced CKD in a mouse model, we achieved specific delivery of a RNLS agonist peptide (RP81) to the renal proximal tubule by encapsulating the peptide in mesoscale nanoparticles (MNPs). We used genetic deletion of RNLS, single-cell RNA sequencing analysis, and Western blotting to determine efficacy and to explore underlying mechanisms. We also measured plasma RNLS in patients with advanced head and neck squamous cell carcinoma receiving their first dose of cisplatin chemother"],"journal":["Journal of the American Society of Nephrology : JASN"],"pubmed_title":["Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation."],"pmcid":["PMC8819981"],"funding_grant_id":["K01DK120783","RC1DK086465","RC1DK086402","R01DK081037","R01 DK081037","RC1 DK086465","P30 CA008748","RC1 DK086402","UL1 TR001863","P30 DK079310","K01 DK120783"],"pubmed_authors":["Xu L","Chen TM","Safirstein R","Williams RM","Guo X","Heller DA","Burtness B","Desir GV","Velazquez H"],"additional_accession":[]},"is_claimable":false,"name":"Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.","description":"Background
Repeated administration of cisplatin causes CKD. In previous studies, we reported that the kidney-secreted survival protein renalase (RNLS) and an agonist peptide protected mice from cisplatin-induced AKI.Methods
To investigate whether kidney-targeted delivery of RNLS might prevent cisplatin-induced CKD in a mouse model, we achieved specific delivery of a RNLS agonist peptide (RP81) to the renal proximal tubule by encapsulating the peptide in mesoscale nanoparticles (MNPs). We used genetic deletion of RNLS, single-cell RNA sequencing analysis, and Western blotting to determine efficacy and to explore underlying mechanisms. We also measured plasma RNLS in patients with advanced head and neck squamous cell carcinoma receiving their first dose of cisplatin chemother","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-19T17:57:24.581Z","creation":"2025-04-19T17:57:24.581Z"},"accession":"S-EPMC8819981","cross_references":{"pubmed":["34921111"],"doi":["10.1681/ASN.2021040439","10.1681/asn.2021040439"]}}